Publications

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

Virtual Oral Presentation

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

Event Websitehttps://event.eortc.org/ena2020/
Access: Free with registration
Session Title: Next Generation Targeted Therapies A
Saturday, October 24th, 22:00 – 23:20 CEST (4 PM – 5:20PM EDT), Channel 1

Save this Presentation
Download PDF

Other Related Resources

Founder’s Letters

Notes from the Trail Read More

Founder’s Letters

Assembling the Team Read More

Founder’s Letters

Introducing Elevation Oncology Read More

Founder’s Letters

Laying the groundwork Read More
Publications